Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
A phase 1/2 trial of JMT108 in melanoma, run by Shanghai JMT-Bio Inc., now recruiting.
Overview
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors is a phase 1/2 interventional study registered as NCT07280832 by Shanghai JMT-Bio Inc., with 500 participants planned, started 2025-12-17 and due to reach its primary completion in 2026-11-30. Interventions recorded: JMT108.
Similar pages
not linked directly; found by shared links- TrialClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialKN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialA Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialSirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.
- TrialFirst-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Shares CSPC Pharmaceutical Group and the tag pipeline.